Literature DB >> 19343138

First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues.

Philip A Philip1.   

Abstract

Entities:  

Year:  2009        PMID： 19343138      PMCID： PMC2661127     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  4 in total

1.  Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.

Authors:  Thomas H Cartwright; Allen Cohn; Jerry A Varkey; Yin-Miao Chen; Ted P Szatrowski; John V Cox; Joseph J Schulz
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

2.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

3.  Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study.

Authors:  V Heinemann; R Labianca; A Hinke; C Louvet
Journal:  Ann Oncol       Date:  2007-07-28       Impact factor: 32.976

4.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Authors:  Richard Herrmann; György Bodoky; Thomas Ruhstaller; Bengt Glimelius; Emilio Bajetta; Johannes Schüller; Piercarlo Saletti; Jean Bauer; Arie Figer; Bernhard Pestalozzi; Claus-Henning Köhne; Walter Mingrone; Salomon M Stemmer; Karin Tàmas; Gabriela V Kornek; Dieter Koeberle; Susanne Cina; Jürg Bernhard; Daniel Dietrich; Werner Scheithauer
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.